Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Semin Cancer Biol. 2011 Sep 18;21(5):335–346. doi: 10.1016/j.semcancer.2011.09.008

Fig. 1.

Fig. 1

Major cellular pathways for targeted therapy of MCL. Intracellular location of aberrant pathways is shown in the center. Around this, individual pathways are highlighted. Pathway-specific inhibitors (mostly limited to clinical grade inhibitors) are boxed. Activating connections are indicated by arrows, inhibitory effects are depicted by lines.